Science
Ezra Cohen: Treatments for Salivary Ductal Carcinoma are Expanding
Ezra Cohen/LinkedIn

Ezra Cohen: Treatments for Salivary Ductal Carcinoma are Expanding

Ezra Cohen, Chief Medical Officer of Oncology at Tempus Labs, shared on LinkedIn:

”Treatments for salivary ductal carcinoma are expanding. This is an aggressive form of salivary gland cancer and, along with HER2 targeting, androgen blockade offers another option in cancers that express the androgen receptor. Great news for patients.”

Title: Darolutamide Alone and in Combination With Goserelin in Androgen Receptor–Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial

Authors: Susumu Okano, Makoto Tahara, Kiyoaki Tsukahara, Tomoyuki Otsuka, Satoshi Kano, Masato Nagaoka, Hideoki Uryu, Daisuke Sano, Naoki Nishio, Kazuchika Ono, Akira Ohkoshi, Toyoyuki Hanazawa, Satoru Shinoda, Yuriko Takeda, Kouji Yamamoto, Naomi Kiyota

Read the full article.

Ezra Cohen: Treatments for Salivary Ductal Carcinoma are Expanding

Other articles about Salivary Gland Carcinoma on OncoDaily.

Akira Ohkoshi cancer Daisuke Sano Ezra Cohen HER2 Hideoki Uryu Kazuchika Ono Kiyoaki Tsukahara Kouji Yamamoto Makoto Tahara Masato Nagaoka Naoki Nishio Naomi Kiyota OncoDaily Oncology Salivary Gland Carcinoma Satoru Shinoda Satoshi Kano Susumu Okano Tomoyuki Otsuka Toyoyuki Hanazawa Yuriko Takeda